Tunneling nanotubes: an alternate route for propagation of the bystander effect following oncolytic viral infection

Molecular Therapy Oncolytics 2016 December [Link] Ady J, Thayanithy V, Mojica K, Wong P, Carson J, Rao P, Fong Y, Lou E Abstract Tunneling nanotubes (TNTs) are ultrafine, filamentous actin-based cytoplasmic extensions which form spontaneously to connect cells at short and long-range distances. We have previously described long-range intercellular communication via TNTs connecting mesothelioma cells…

Read More

Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment

European Respiratory Review 2016 December [Link] Bibby AC, Tsim S, Kanellakis N, Ball H, Talbot DC, Blyth KG, Maskell NA, Psallidas Abstract Malignant pleural mesothelioma is an aggressive malignancy of the pleural surface, predominantly caused by prior asbestos exposure. There is a global epidemic of malignant pleural mesothelioma underway, and incidence rates are predicted to…

Read More

Accelerated cell cycle progression of human regulatory T cell-like cell line caused by continuous exposure to asbestos fibers

International Journal of Oncology 2016 November 22 [Epub ahead of print] [Link] Lee S, Matsuzaki H, Maeda M, Yamamoto S, Kumagai-Takei N, Hatayama T, Ikeda M, Yoshitome K, Nishimura Y, Otsuki T Abstract Asbestos exposure causes malignant tumors such as lung cancer and malignant mesothelioma. Based on our hypothesis in which continuous exposure to asbestos…

Read More

Intrapleural Adenoviral-mediated Endothelial Cell Protein C Receptor Gene Transfer Suppresses the Progression of Malignant Pleural Mesothelioma in a Mouse Model

Scientific Reports 2016 November 11 [Link] Keshava S, Rao LV, Pendurthi UR Abstract Malignant pleural mesothelioma (MPM) is an aggressive thoracic cancer with a high mortality rate as it responds poorly to standard therapeutic interventions. Our recent studies showed that expression of endothelial cell protein C receptor (EPCR) in MPM cells suppresses tumorigenicity. The present…

Read More

Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis

Cancer Letters 2016 October [Epub ahead of print] [Link] Tanaka K, Osada H, Murakami-Tonami Y, Horio Y, Hida T, Sekido Y Abstract Malignant mesothelioma (MM) frequently exhibits Hippo signaling pathway inactivation (HPI) mainly due to NF2 and/or LATS2 mutations, which leads to the activation of YAP transcriptional co-activator. Here, we show antitumor effects of statin…

Read More

What is the role of a specialist regional mesothelioma multidisciplinary team meeting? A service evaluation of one tertiary referral centre in the UK

British Medical Journal 2016 September 8 [Link] Bibby AC, Williams K, Smith S, Bhatt N, Maskell NA Abstract BACKGROUND: Multidisciplinary team meetings are standard care for cancer in the UK and Europe. Professional bodies recommend that mesothelioma cases should be discussed at specialist multidisciplinary team meetings. However, no evidence exists exploring the role of the…

Read More

Standardization of incidence rates of mesothelioma in the absence of national standards: sensitivity analysis in a cohort formerly exposed to asbestos

La Medicina del lavoro 2016 July 26 [Link] Barbiero F, Giangreco M, Pisa FE, Negro C, Bovenzi M, Rosolen V, Barbone F Abstract INTRODUCTION: The incidence of mesothelioma in Italy shows wide geographical variation, with the highest incidence rates in Genoa and Friuli Venezia Giulia (FVG). For mesothelioma, national standard incidence rates are not available…

Read More

Establishment of anti-mesothelioma monoclonal antibodies

BMC Research Notes [Epub ahead of print] [Link] Mizutani N, Abe M, Matsuoka S, Kajino K, Wakiya M, Ohtsuji N, Hatano R, Morimoto C, Hino O. Abstract BACKGROUND: Mesotheliomas are aggressive, therapy-resistant tumors that are predicted to increase in incidence at least until 2020. The prognosis of patients with mesothelioma is generally poor because they…

Read More